Form 4: Disc Medicine COO Sells Shares Under 10b5-1 Plan

Disc Medicine COO Jonathan Yen-Wen Yu reports sale of 9,700 common shares and acquisition of 9,700 shares via stock option exercise under a pre-arranged trading plan.

Summary

• Jonathan Yen-Wen Yu, Chief Operating Officer of Disc Medicine, Inc., executed a Rule 10b5-1 trading plan on March 17, 2026.
• On June 22, 2026, Yu acquired 9,700 shares of common stock at a price of $13.50 per share.
• On the same date, Yu sold 9,700 shares of common stock at a weighted average price of $72.6593, with individual sale prices ranging from $72.50 to $72.68.
• Following these transactions, Yu beneficially owns 54,324 shares of common stock directly.
• The stock option acquired has an exercise price of $13.50 and an expiration date of December 28, 2032.
• The underlying shares for the stock option vest in 48 equal monthly installments starting from December 29, 2022, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While the sale of shares by an executive can be a negative signal, the execution under a Rule 10b5-1 plan mitigates concerns about insider trading, and the option exercise represents a planned financial event.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially non-insider trading related activity.
• The acquisition of shares via stock option exercise at a lower price ($13.50) than the sale price ($72.6593) represents a profitable transaction for the reporting person.

Negatives

• A significant number of shares (9,700) were sold by a key executive, which could be perceived negatively by the market.
• The sale price of $72.6593 is substantially higher than the acquisition price of $13.50 for the option, indicating a significant gain for the executive.

Risks

• The sale of shares by a Chief Operating Officer could be interpreted as a lack of confidence in the company's future prospects by management, although it was executed under a pre-arranged plan.
• The vesting schedule of the stock options implies continued service is required, and any departure before vesting would result in forfeiture of unvested options.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's future performance. The future outlook for the reporting person's holdings is tied to the vesting schedule of the remaining stock options and the company's stock performance.

Management Comments

• The transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

Industry Context

StockSavvy.ai notes that the use of Rule 10b5-1 plans is a common practice for corporate insiders to sell shares in a pre-determined manner, aiming to avoid accusations of insider trading. The significant spread between the option exercise price and the sale price suggests a substantial gain for the executive, which is typical for stock options granted at a lower strike price.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a COO as a potential negative signal, although the Rule 10b5-1 plan provides a mitigating context.
• Employees: The vesting schedule of options for the COO indicates continued commitment, which can be seen as positive for employee morale and company stability.
• Management: The transaction highlights the financial benefits derived by management from equity compensation, which is a standard aspect of executive compensation.

Next Steps

• The reporting person's remaining stock options will continue to vest according to the schedule, subject to continued service.
• The company's stock performance will determine the future value of the reporting person's remaining holdings and unvested options.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Stock Option, Share Sale, Disc Medicine, Jonathan Yen-Wen Yu, Beneficial Ownership, SEC Filing